Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review

SIMPLE SUMMARY: PDAC is one of the most malignant tumors and its treatment, whether surgery or chemotherapy, has shown poor results. Resistance to gemcitabine and other chemotherapeutic drugs is an essential factor in this failure. This review analyzes the molecular causes of gemcitabine resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Koltai, Tomas, Reshkin, Stephan Joel, Carvalho, Tiago M. A., Di Molfetta, Daria, Greco, Maria Raffaella, Alfarouk, Khalid Omer, Cardone, Rosa Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139729/
https://www.ncbi.nlm.nih.gov/pubmed/35626089
http://dx.doi.org/10.3390/cancers14102486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139729/
https://www.ncbi.nlm.nih.gov/pubmed/35626089
http://dx.doi.org/10.3390/cancers14102486

Ejemplares similares